GAL and hepatocellular carcinoma: To further elucidate the role of Gal-1 in HCC cell resistance to sorafenib, HCCLM3 and MHCC97H cells, which exhibit high levels of Gal-1 protein expression, were treated with Gal-1 shRNA.